Ho-Lien Huang

Title: Ho-Lien Huang: Innovator in Radiochemistry and Tumor Imaging

Introduction

Ho-Lien Huang is a prominent inventor based in Hsinchu, Taiwan. He has made significant contributions to the field of radiochemistry, particularly in the development of innovative methods for tumor imaging. With a total of 3 patents, his work has the potential to enhance the accuracy of cancer diagnostics.

Latest Patents

One of his latest patents involves a method for preparing [I]Iodooctyl fenbufen amide. This invention boasts a radiochemical yield of 15%, a specific activity of 37 GBq/μmol, and a radiochemical purity of 95%. This compound is utilized as a tracer in single photon emission computed tomography (SPECT) to estimate the distribution of cyclooxygenase, which is crucial for assessing tumor development and metastasis. Another notable patent is a tumor radiation probe of iodine-123 marker thymidine (FLT) analogue [I]-IaraU. This innovative probe is synthesized using commercially available uridine and has achieved a radiochemical purity of over 98% and a yield increase from 8% to 40%, making it suitable for biological experiments while reducing production costs.

Career Highlights

Ho-Lien Huang has worked with esteemed institutions such as Tsinghua University and the Institute of Nuclear Energy Research, Atomic Energy Council. His expertise in radiochemistry has positioned him as a key figure in the development of advanced imaging techniques for cancer diagnostics.

Collaborations

Throughout his career, Huang has collaborated with notable colleagues, including Chung-Shan Yu and Ching-Shiuann Yang. These partnerships have furthered his research and contributed to the advancement of innovative solutions in the field.

Conclusion

Ho-Lien Huang's contributions to radiochemistry and tumor imaging exemplify the impact of innovation in medical diagnostics. His patents reflect a commitment to improving cancer detection methods, ultimately benefiting patients and the medical community.